Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab add-on therapy in severe persistent asthma
2014-004932-20Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in severe asthma comparing Risankizumab add-on therapy with Placebo add-on therapy (2 arms). Primary endpoint: Time to first asthma worsening. Started Apr 2015; status: completed.
02
Drugs
risankizumab
03
Conditions
severe asthma
Beyond the preview
Go deeper on 2014-004932-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004932-20.